Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
BörsenkürzelPRE
Name des UnternehmensPrenetics Global Ltd
IPO-datumJul 06, 2021
CEOMr. Joel Neoh
Anzahl der mitarbeiter285
WertpapierartOrdinary Share
GeschäftsjahresendeJul 06
AddresseUnit 703-706, K11 Atelier King's Road, 728 King's Road, Quarry Bay
Stadt
BörseLondon Stock Exchange
LandHong Kong
Postleitzahl- -
Telefon85222109588
Websitehttps://ir.prenetics.com/
BörsenkürzelPRE
IPO-datumJul 06, 2021
CEOMr. Joel Neoh
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten